Evolution within the
Advice
of Administration
Paris
,
the
5
September 2022.
Sanofi’s Board of Directors met on September 2, 2022 and unanimously appointed Frédéric Oudéa as Observer with effect from that date.
Furthermore, the appointment of Frédéric Oudéa as a director will be submitted for approval at the next General Meeting. Following this General Meeting, it will be proposed to the Board of Directors of Sanofi the appointment of Frédéric Oudéa as non-executive Chairman of this Board, replacing Serge Weinberg whose term of office will have expired. Frédéric Oudéa has announced that he will step down as Chief Executive Officer and director of Société Générale in May 2023.
Serge Weinberg
President of Sanofi
”
I rejoice that
Frederic
Oudea
has agreed to join the Board of Directors as a non-voting member and then, if the General Meeting agrees, become a director and succeed me as Chairman of the Board. His experience leading and leading the digital transformation of a large international group in a sector
strongly
regulated, his understanding of governance issues, his financial skills, his integrity, his rigor and his sense of responsibility make me confident of his success in his future role.
.
Frederic
Oudea
and
Paul Hudson,
Chief Executive Officer of Sanofi, will form an excellent duo to position Sanofi as a modern healthcare company and strengthen its position as a French, European and global leader in the service of patients
.
»
F
rederic
O
udea
Chief Executive Officer of Societe Generale
”
I
am very happy to join the Board of Directors of Sanofi as a non-voting member, with, subject to the agreement of its shareholders, the prospect of taking over as Chairman, and thank the Board of Directors and its Chairman Serge Weinberg for their trust. I am extremely motivated by the prospect of contributing in the coming years to the strategy and sustainable development of Sanofi, a leading company in a strategic health sector, with high impact and in full transformation, and to be the guarantor of quality
group governance
“.
Frédéric Oudéa was born on July 3, 1963. He is a former student of the Ecole Polytechnique and the Ecole Nationale d’Administration. Frédéric Oudéa is Chief Executive Officer of Société Générale, which he joined in 1996. He was successively Deputy Head then Head of the Corporate Banking Department in the United Kingdom, Head of Global Supervision and Development of the Equities business, Deputy Chief Financial Officer then Chief Financial Officer in 2003, before becoming Chief Executive Officer of the group in 2008, and Chairman and Chief Executive Officer in 2009. On the occasion of the separation of functions imposed for regulatory reasons on systemic banks in Europe, he was appointed Chief Executive Officer in 2015. Before joining Société Générale, he worked for 8 years in Administration, first at the Finance Inspectorate, then at the Ministry of the Budget. Frédéric Oudéa is also lead director of Capgemini.
To
in relation to
Sanofi
We are an innovative, global health company driven by one purpose: to pursue the miracles of science to improve people’s lives. Our teams, present in a hundred countries, are working to transform the practice of medicine to make the impossible possible. We provide therapeutic solutions that can change the lives of patients and vaccines that protect millions of people around the world, guided by the ambition of sustainable development and our social responsibility.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media relations
Sandrine Guendoul
| + 33 6 25 09 14 25 |
Nicholas Obrist
| + 33 6 77 21 27 55 |
Victor Rouault
| + 33 6 70 93 71 40 |
Investor Relations
Eva Schaefer-Jansen
| + 33 7 86 80 56 39 | [email protected]
Arnaud
Delepine
| + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt
| + 33 6 40 56 92 21 | [email protected]
Felix Lauscher
| + 1 908 612 7239 | [email protected]
Priya Nanduri
| +1 617 764 6418 | [email protected]
Nathalie Pham
| + 33 7 85 93 30 17 | [email protected] m
Attachment